Topical corticosteroids are among the most commonly used medications in dermatology because of their potent anti-inflammatory, immunosuppressive, and vasoconstrictive effects. They are used to treat a wide range of inflammatory skin disorders, including eczema, dermatitis, psoriasis, and other corticosteroid-responsive conditions.
Although topical corticosteroids share similar mechanisms of action, they differ considerably in potency. Selecting the appropriate corticosteroid requires consideration of the diagnosis, severity of disease, anatomical location, treatment duration, and risk of adverse effects.
Topical corticosteroids are commonly divided into potency classes ranging from Class I to Class VII. Class I agents are the most potent, while Class VII agents are the least potent.
The relative potency of a topical corticosteroid is largely determined by its vasoconstrictive activity. For example, a highly potent corticosteroid such as betamethasone produces substantially greater vasoconstriction than a lower-potency medication such as hydrocortisone.
| Potency Category | Class | Examples |
|---|---|---|
| Low potency | Classes V–VII | Hydrocortisone 0.5%, 1%, or 2.5%; fluocinolone acetonide 0.01%; desonide 0.05%; triamcinolone acetonide 0.025%; hydrocortisone butyrate 0.1%; hydrocortisone valerate 0.2%; triamcinolone acetonide 0.1% |
| Midrange potency | Classes III–IV | Augmented betamethasone dipropionate 0.05% cream; mometasone furoate 0.1% ointment; amcinonide 0.1% |
| High potency | Class II | Fluocinolone acetonide 0.2%; desoximetasone 0.25%; fluocinonide 0.05%; augmented betamethasone dipropionate 0.05% gel or ointment |
| Super-high potency | Class I | Clobetasol propionate 0.05%; halobetasol propionate 0.05% |
The potency of a topical corticosteroid should be matched to the severity and type of dermatologic disorder. In general, higher-potency corticosteroids are reserved for more difficult-to-treat or thickened inflammatory conditions.
Higher-potency agents, particularly Classes I through III, may be used for conditions such as:
These disorders may require greater anti-inflammatory activity because of substantial inflammation, thickened skin, or reduced penetration of topical medications.
Medium-potency topical corticosteroids, generally within Classes IV and V, are frequently used for common inflammatory dermatologic disorders. They provide meaningful anti-inflammatory effects while generally carrying less risk than prolonged use of higher-potency agents.
Conditions commonly treated with medium-potency corticosteroids include:
Low-potency corticosteroids, particularly Classes VI and VII, are generally preferred when treatment involves areas with thinner or more permeable skin. These anatomical regions absorb topical medications more readily and are therefore more susceptible to corticosteroid-related adverse effects.
Lower-potency agents are commonly used on areas such as:
Clinical Pearl: The thinner the skin and the greater its permeability, the more cautiously topical corticosteroids should be prescribed. High-potency preparations are generally inappropriate for prolonged use on the face, eyelids, genital region, or skin folds.
The effectiveness of a topical corticosteroid can be increased by applying an occlusive dressing over the treated area. Occlusion increases hydration of the stratum corneum and can substantially enhance penetration of the medication into the skin.
Although this can improve therapeutic effectiveness, increased penetration also increases the risk of adverse effects. Occlusion should therefore be used selectively and with consideration of the corticosteroid’s potency, treatment area, and duration of therapy.
One of the most important complications associated with excessive or prolonged topical corticosteroid use is cutaneous and subcutaneous tissue atrophy. The risk increases with greater corticosteroid potency, prolonged treatment, use on thin skin, and occlusive therapy.
Important Safety Point: Because of the risk of tissue atrophy, super-high-potency topical corticosteroids should generally not be used continuously for more than approximately 3 weeks unless treatment is specifically directed and monitored by a clinician.
Low-, medium-, and high-potency topical corticosteroids may sometimes be used for longer treatment courses, but prolonged continuous therapy should still be avoided whenever possible. Extended corticosteroid exposure can lead to adverse effects including skin thinning and subcutaneous tissue atrophy.
The goal of topical corticosteroid therapy is to use a preparation that provides sufficient anti-inflammatory activity while minimizing unnecessary exposure to a medication that is more potent than required. In practice, clinicians should generally use the lowest potency capable of effectively controlling the condition, particularly when treating sensitive anatomical areas or when therapy is expected to continue for an extended period.
Higher-potency corticosteroids can be highly effective for resistant or thickened inflammatory disorders, but their use should generally be limited in duration. Lower-potency agents are more appropriate for thin or highly absorbent areas such as the face and skin folds.
Key Point: Topical corticosteroid therapy should be individualized according to potency, diagnosis, anatomical location, treatment duration, formulation, and the use of occlusion. Greater potency can improve therapeutic effectiveness, but it also increases the importance of careful prescribing and monitoring for adverse effects.
James WD, Elston DM, Treat JR, Rosenbach M, Neuhaus IM. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed. Philadelphia, PA: Elsevier; 2019.
Robertson D, Maibach H. Dermatologic pharmacology. In: Katzung B, ed. Katzung’s Basic and Clinical Pharmacology. 14th ed. New York, NY: McGraw-Hill Medical; 2018:1068–1086.
Stringer J. Adrenocortical hormones. In: Stringer J, ed. Basic Concepts in Pharmacology. 5th ed. New York, NY: McGraw-Hill Medical; 2017:185–188.
Benson HA, Watkinson AC. Topical and Transdermal Drug Delivery: Principles and Practice. Hoboken, NJ: John Wiley & Sons; 2012:357–366.
